Free shipping on all orders over $ 500

Tofersen

Cat. No. M21583
Tofersen Structure
Synonym:

BIIB067; ISIS-SOD1Rx

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Tofersen (BIIB067) is an antisense oligonucleotide that mediates RNase H-dependent degradation of superoxide dismutase 1 (SOD1) mRNA to reduce SOD1 protein synthesis. Tofersen can be used in amyotrophic lateral sclerosis (ALS) research.

Chemical Information
Molecular Weight 7128.00
CAS Number 2088232-70-4
Solubility (25°C) Water ≥ 60 mg/mL
Storage -20°C, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Timothy M Miller, et al. N Engl J Med. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

[2] Johannes Dorst, et al. Curr Opin Neurol. Clinical studies in amyotrophic lateral sclerosis

[3] Michael Benatar, et al. Neurotherapeutics. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study

[4] Daisuke Ito. Ann Neurol. Promise of Nucleic Acid Therapeutics for Amyotrophic Lateral Sclerosis

[5] Timothy Miller, et al. N Engl J Med. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

Related DNA/RNA Synthesis Products
PR-104

PR-104 is a novel hypoxia-activated DNA cross-linking agent with marked activity against human tumor xenografts, both as monotherapy and combined with radiotherapy and chemotherapy.

D-I03

D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 µM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC50s of 5 µM and 8 µM, respectively.

Bractoppin

Bractoppin is a potent and selective inhibitor of phosphopeptide recognition by the human BRCA1 tandem(t) BRCT domain with IC50 of 74 nM. Bractoppin diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51.

Plitidepsin

Plitidepsin (Aplidine) is a potent anticancer compound targeting eEF1A2 (KD=80 nM). Plitidepsin has antiviral activity, and the IC90 of inhibiting SARS-CoV-2 is 0.88 nM. Plitidepsin is commonly used in multiple myeloma and advanced cancer research and has potential for COVID-19 research.

ART812

ART812 is an orally effective DNA polymerase Polθ inhibitor with an IC50 value of 7.6 nM. ART812 had an IC50 value of 240 nM for cell-based microhomologous mediated end-junction (MMEJ).

  Catalog
Abmole Inhibitor Catalog




Keywords: Tofersen, BIIB067; ISIS-SOD1Rx supplier, DNA/RNA Synthesis, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.